News Welsh firm Antiverse raises funds for AI antibody platform Cardiff's Antiverse has raised $9.3m to develop its AI-based design platform for antibodies against hard-to-reach targets like GPCRs and ion channels.
News Chai raises $130m for AI drug discovery platform AI specialist Chai Discovery has said it is sitting on a valuation of around $1.3 billion, after raising $130 million in a Series B financing.
News Epsilogen buys rival cancer antibody firm TigaTx Epsilogen has bought TigaTx, pooling their resources to create what it says will be a leader in 'pan-isotope' cancer antibodies.
News Roche taps Oxford BioTherapeutics for cancer drug discovery Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.
News J&J abandons work with Genmab on Darzalex successor Genmab is facing increased pressure to deliver on its in-house pipeline after Johnson & Johnson exited a partnership on a Darzalex follow-up.
News AMD shadows NVIDIA with a move into AI drug discovery Chipmaker AMD has taken a 20% stake in Absci, a specialist in the use of artificial intelligence in for biologic drug discovery.
News Novartis snaps up PI3Kα breast cancer drug in $3bn deal Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.